Axil Life Science & Healthcare Fund II

Axil Life Science & Healthcare Fund II is a Tokyo-based venture capital firm specializing in biomedical and healthcare technology investments. The firm focuses on supporting the growth of early-stage ventures by leveraging its global network and resources. Axil Capital was spun out of Mizuho Securities in 2017, with early investors that include Mizuho, the Japanese government, a global pharmaceutical company, and a small group of corporate visionaries from inside and outside of Japan. The firm's goal is to create synergies between the biotech ecosystem in Japan and the rest of the world, resulting in great companies and great returns for its investors. The firm's investment strategy spans the full spectrum of the life science industry, including biopharmaceuticals, platform technologies, medical devices, digital health, and healthcare services. Axil Capital diversifies its portfolio by investing in early-stage venture capital as well as late-stage crossover round deals. The firm focuses on transformational technologies and services that can have a long-term impact on the medical community and society at large while generating tangible returns to its investors. Axil Capital's recent activities include the launch of its second fund, Axil Life Science & Healthcare Fund II (ALHF II), in November 2022. The fund aims to produce world-class companies from Japan by liaising with the global venture ecosystem and enabling the venture managers to adopt a global perspective focused on commercial success. In August 2024, ALHF II completed its third closing in collaboration with Fannin Innovation, a leading U.S. Texas-based life science venture studio. This strategic partnership enhances ALHF II's ability to invest in transformative biotech solutions while fostering cross-border collaboration between Japan and the U.S. Additionally, in March 2023, the Organization for Small & Medium Enterprises and Regional Innovation, JAPAN (SMRJ) announced an investment of up to ¥2.0 billion in ALHF II, demonstrating continued support for the firm's endeavors in fostering the growth of the health and medical venture ecosystem. Axil Capital's portfolio companies include Elixiron Immunotherapeutics, which successfully completed its IPO listing on the Emerging Stock Board of Taipei Exchange in January 2026, and DT Axis, LinqMed, Y4, MabGenesis, Pulmotect, and CynosBio, Inc. These investments reflect Axil Capital's commitment to advancing innovative solutions in the biomedical and healthcare sectors, contributing to the development of world-class life science ventures in Japan and globally.

Focus on biomedical and healthcare technology sectors, Early-stage to late-stage investment opportunities, Global market potential, Innovative and transformative technologies, Strong management teams